User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 17:52, 24 June 2019 (diff | hist) . . (+66) . . m Multiple myeloma, consolidation and maintenance (current)
- 17:52, 24 June 2019 (diff | hist) . . (+1,053) . . m Multiple myeloma - historical (→Observation) (current)
- 17:48, 24 June 2019 (diff | hist) . . (+15) . . m Multiple myeloma - historical (→References)
- 17:44, 24 June 2019 (diff | hist) . . (+945) . . m Gastric cancer (→S-1 monotherapy {{#subobject:ec10ef|Regimen=1}}) (current)
- 17:37, 24 June 2019 (diff | hist) . . (+5) . . m Paroxysmal nocturnal hemoglobinuria (→Ravulizumab monotherapy {{#subobject:abd213 |Regimen=1}}) (current)
- 17:37, 24 June 2019 (diff | hist) . . (-28) . . m Paroxysmal nocturnal hemoglobinuria (→Investigational agents)
- 17:37, 24 June 2019 (diff | hist) . . (+3,962) . . Paroxysmal nocturnal hemoglobinuria (→All lines of therapy)
- 17:24, 24 June 2019 (diff | hist) . . (+95) . . N Category:FDA approved in 1944 (Created page with "Drugs, devices, and/or biologics FDA approved in 1944. Category:FDA approved in the 1940's") (current)
- 17:23, 24 June 2019 (diff | hist) . . (+176) . . N Penicillin V (Created page with "An antibiotic. Category:Drugs Category:Oral medications Category:Penicillin Category:FDA approved in 1944 Category:WHO Essential Anti-infective Medicines") (current)
- 17:17, 24 June 2019 (diff | hist) . . (+1,940) . . N Ravulizumab (Ultomiris) (Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/complement-c5-inhibitor-alxn1210 NCI Drug Dictionary]: A lon...") (current)
- 17:12, 24 June 2019 (diff | hist) . . (+59) . . m Drug index (→R) (current)
- 17:09, 24 June 2019 (diff | hist) . . (+26) . . m Drug index (→C)
- 17:08, 24 June 2019 (diff | hist) . . (+40) . . m Folinic acid (Leucovorin) (→Also known as) (current)
- 16:57, 24 June 2019 (diff | hist) . . (+115) . . m Small cell lung cancer - historical (→CAV {{#subobject:cbb2ff|Regimen=1}}) (current)
- 16:52, 24 June 2019 (diff | hist) . . (+15) . . m Amsacrine (Amsidine) (→Also known as) (current)
- 12:52, 24 June 2019 (diff | hist) . . (+102) . . m Small cell lung cancer - historical (→ACE {{#subobject:9fbf31|Regimen=1}})
- 12:10, 24 June 2019 (diff | hist) . . (-46) . . m Soft tissue sarcoma (→Doxorubicin & Ifosfamide {{#subobject:e28770|Regimen=1}}) (current)
- 12:02, 24 June 2019 (diff | hist) . . (+76) . . m Acute myeloid leukemia (→Upfront induction therapy, standard and older "fit" patients) (current)
- 20:24, 23 June 2019 (diff | hist) . . (+53) . . m Esophageal cancer (current)
- 20:20, 23 June 2019 (diff | hist) . . (+28) . . m Myelodysplastic syndrome (current)
- 20:06, 23 June 2019 (diff | hist) . . (+12) . . m Waldenström macroglobulinemia (current)
- 20:06, 23 June 2019 (diff | hist) . . (+12) . . m Follicular lymphoma (current)
- 20:05, 23 June 2019 (diff | hist) . . (+12) . . m Marginal zone lymphoma (current)
- 20:03, 23 June 2019 (diff | hist) . . (+33) . . m Mesothelioma (current)
- 19:48, 23 June 2019 (diff | hist) . . (+354) . . m Breast cancer, HER2-positive (current)
- 19:48, 23 June 2019 (diff | hist) . . (+22) . . m Complex multipart regimens (→References) (current)
- 19:47, 23 June 2019 (diff | hist) . . (+22) . . m Complex multipart regimens (→References)
- 19:42, 23 June 2019 (diff | hist) . . (+75) . . m Prostate cancer - historical (→Castration) (current)
- 19:40, 23 June 2019 (diff | hist) . . (+67) . . m Esophageal cancer
- 19:39, 23 June 2019 (diff | hist) . . (+50) . . m Gastric cancer
- 19:26, 23 June 2019 (diff | hist) . . (+384) . . m Peripheral T-cell lymphoma (current)
- 19:25, 23 June 2019 (diff | hist) . . (0) . . N File:NShah.png (current)
- 10:53, 23 June 2019 (diff | hist) . . (+2) . . m Small cell lung cancer - historical
- 10:52, 23 June 2019 (diff | hist) . . (+10) . . m Small cell lung cancer
- 10:50, 23 June 2019 (diff | hist) . . (+127) . . m Acute myeloid leukemia
- 14:42, 22 June 2019 (diff | hist) . . (+239) . . m Ontology (→References and acknowledgements)
- 12:28, 22 June 2019 (diff | hist) . . (+385) . . m Gallbladder cancer (→Adjuvant therapy)
- 12:25, 22 June 2019 (diff | hist) . . (+125) . . m T-cell acute lymphoblastic leukemia (→Guidelines)
- 12:24, 22 June 2019 (diff | hist) . . (+872) . . m B-cell acute lymphoblastic leukemia, Ph-positive
- 12:23, 22 June 2019 (diff | hist) . . (+125) . . m B-cell acute lymphoblastic leukemia (→NCCN)
- 12:07, 22 June 2019 (diff | hist) . . (-5) . . m Hereditary hemorrhagic telangiectasia (→Tamoxifen acid monotherapy {{#subobject:b1894c|Regimen=1}}) (current)
- 18:38, 21 June 2019 (diff | hist) . . (+14) . . m Diffuse large B-cell lymphoma - historical
- 18:36, 21 June 2019 (diff | hist) . . (-45) . . m Waldenström macroglobulinemia
- 18:34, 21 June 2019 (diff | hist) . . (-28) . . m Follicular lymphoma - historical
- 18:32, 21 June 2019 (diff | hist) . . (-68) . . m Small cell lung cancer - historical
- 18:27, 21 June 2019 (diff | hist) . . (+21) . . m Testicular cancer
- 18:22, 21 June 2019 (diff | hist) . . (+38) . . m Hodgkin lymphoma - historical
- 18:20, 21 June 2019 (diff | hist) . . (+2) . . m Carboplatin & gemcitabine for unresectable or metastatic bladder cancer
- 18:19, 21 June 2019 (diff | hist) . . (+2) . . m Bladder cancer
- 10:57, 21 June 2019 (diff | hist) . . (+14) . . m Mantle cell lymphoma (→PEP-C {{#subobject:e8f271|Regimen=1}})
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
